A biopharma company using gene therapy faced growing GxP validation demands from frequent SaaS updates. To ease the burden, they partnered with Sware to deploy the Res\_Q platform, enabling automation and centralization of validation processes. This reduced manual effort by 102 FTE hours per project, eliminated paper workflows, and improved change management and audit readiness. Res\_Q also provided flexibility to scale and visibility across systems. With expert support from Sware, the company improved compliance, accelerated adoption, and freed up internal teams to focus on high-priority initiatives.

Join for free to read